Profound Medical Corp.
Profound Medical Corp.
Your view on PROF
Overview
What the company does, where it operates, and who runs it.
About Profound Medical Corp.
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Arun Swarup Menawat MBA,
- Headquarters
- 2400 Skymark Avenue, Mississauga, ON, CA
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Arun Swarup Menawat MBA,
- Headquarters
- 2400 Skymark Avenue, Mississauga, ON, CA
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland.
Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities.
The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Profound Medical Corp., and the rating behind it. PROF last traded at $5.97; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Profound Medical Corp.. Starting points for Profound Medical Corp.: EPS -$0.89, beta 0.53 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Profound Medical Corp.. Profound Medical Corp. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Profound Medical Corp.. Trailing twelve-month EPS for Profound Medical Corp. stands at -$0.89. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Profound Medical Corp.. Profound Medical Corp. has reported as a listed company since 2019. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Profound Medical Corp. valued side by side against its closest peers. Profound Medical Corp. is measured against Medical - Devices peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Profound Medical Corp., and how their positions are changing. At a $216.9M market value, institutional positions materially move Profound Medical Corp.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Profound Medical Corp. executives and directors. Shares of Profound Medical Corp. have traded between $3.76 and $8.75 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Profound Medical Corp.. Profound Medical Corp. is a $216.9M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Profound Medical Corp.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Profound Medical Corp.. Coverage tracks Profound Medical Corp. within Medical - Devices (Healthcare). Press releases and market coverage, newest first.